Limits...
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).

Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Menter A, PSOLAR Steering Committ - Br. J. Dermatol. (2014)

Bottom Line: Efficacy and safety data are collected every 6 months for 8 years, and data are extracted annually.Diabetes mellitus type II was reported in 11·4% of patients.The occurrence of most comorbidities, including cardiovascular disease and risk factors, increased with age.

View Article: PubMed Central - PubMed

Affiliation: Harvard Medical School and Massachusetts General Hospital, Boston, MA, U.S.A.

Show MeSH

Related in: MedlinePlus

Proportion of patients enrolled in the Psoriasis Longitudinal Assessment and Registry by country.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232924&req=5

fig01: Proportion of patients enrolled in the Psoriasis Longitudinal Assessment and Registry by country.

Mentions: As of the 23 August 2012 PSOLAR data extract, 11 900 of the 12 000 targeted patients were enrolled at 301 global sites in North America, Europe and Latin America. The first patient was enrolled on 20 June 2007. More than 90% of sites are located in North America (i.e. approximately 75·0% in the U.S.A. and approximately 16·0% in Canada) (Fig.1).


Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).

Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Menter A, PSOLAR Steering Committ - Br. J. Dermatol. (2014)

Proportion of patients enrolled in the Psoriasis Longitudinal Assessment and Registry by country.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232924&req=5

fig01: Proportion of patients enrolled in the Psoriasis Longitudinal Assessment and Registry by country.
Mentions: As of the 23 August 2012 PSOLAR data extract, 11 900 of the 12 000 targeted patients were enrolled at 301 global sites in North America, Europe and Latin America. The first patient was enrolled on 20 June 2007. More than 90% of sites are located in North America (i.e. approximately 75·0% in the U.S.A. and approximately 16·0% in Canada) (Fig.1).

Bottom Line: Efficacy and safety data are collected every 6 months for 8 years, and data are extracted annually.Diabetes mellitus type II was reported in 11·4% of patients.The occurrence of most comorbidities, including cardiovascular disease and risk factors, increased with age.

View Article: PubMed Central - PubMed

Affiliation: Harvard Medical School and Massachusetts General Hospital, Boston, MA, U.S.A.

Show MeSH
Related in: MedlinePlus